{"id":"W2951817901","doi":"10.1016/s0140-6736(19)30764-0","title":"Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial","year":2019,"lang":"en","type":"article","venue":"The Lancet","topic":"Musculoskeletal synovial abnormalities and treatments","field":"Medicine","cited_by":474,"is_retracted":false,"has_abstract":false,"ca_institutions":"McGill University","funders":"Daiichi Sankyo Europe; National Cancer Institute; Genentech; Daiichi Sankyo Company; Plexxikon; PharmaMar; Eli Lilly and Company; Ignyta; National Institutes of Health; Istituto Ortopedico Rizzoli di Bologna; Eisai; Celldex Therapeutics; Daiichi-Sankyo; Pfizer; Incyte; Five Prime Therapeutics; EMD Serono; Society of Memorial Sloan Kettering; Karyopharm Therapeutics; Exelixis; Memorial Sloan-Kettering Cancer Center; Amgen; Bristol-Myers Squibb; Foundation for the National Institutes of Health","keywords":"Medicine; Placebo; Clinical endpoint; Evening; Internal medicine; Surgery; Surrogate endpoint; Clinical trial; Randomized controlled trial; Intention-to-treat analysis; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003694617,0.000218772,0.000740033,0.00003192548,0.0001152395,0.00002786579,0.0001833384,0.00006713272,0.0005300053],"category_scores_gemma":[0.0001385946,0.0001304257,0.0003187956,0.00008432563,0.00005082106,0.00006987227,0.00004184811,0.0001586048,0.0002450084],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006559573,"about_ca_system_score_gemma":0.00009293733,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003567807,"about_ca_topic_score_gemma":0.00000815269,"domain_scores_codex":[0.9986046,0.00007325185,0.0003195646,0.000273019,0.0002473167,0.0004822507],"domain_scores_gemma":[0.9987592,0.0004282644,0.0001546488,0.0004798791,0.00005672963,0.000121265],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9796186,0.0005645546,0.00005001019,0.0001828126,0.0001831593,0.00001519346,0.0002125298,0.000008326731,0.01138905,0.0002987953,0.003394907,0.004082027],"study_design_scores_gemma":[0.953602,0.005219859,0.0001435761,0.00005396429,0.0002840362,0.000006366253,0.0001647727,0.0002375298,0.005616701,0.00009171227,0.03440367,0.0001758319],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9740486,0.0001652425,0.00007643182,0.00170871,0.001248411,0.005428733,0.0001422531,0.00008141204,0.01710019],"genre_scores_gemma":[0.9914758,0.00003628226,0.0005350597,0.0003827563,0.002025821,0.0004105589,0.0001226358,0.00003573009,0.004975333],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03100877,"threshold_uncertainty_score":0.5803186,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03192777351594508,"score_gpt":0.3229573369635507,"score_spread":0.2910295634476056,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}